Option Care Health
OPCH
31.01
+0.01
+0.03%
Option Care Health
US · OPCH
#2386 by market cap
Listed 1970
31.01
+0.01
+0.03%
Live - 5344 symbols - heartbeat 480s ago
· 2026-10-08 08:16
Pre-market
31.01
0.00%
After-hours
31.04
+0.10%
Overnight
30.71
-0.97%
- Market cap
- 4.65B
- P/E (TTM)i
- 23.49
- P/Bi
- 3.69
- EPSi
- 1.27
- Div yieldi
- 0.00%
- 52W posi
- 69%
Reader sentiment
Are you bullish or bearish on OPCH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 3.77, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +13.03% YoY
Margins
- Gross margin
- 19.26%
- Operating margin
- 5.98%
- Net margin
- 3.67%
Key ratios & quality
- Enterprise valuei
- 5.60B
- PEG ratioi
- 2.08
- Altman Z-Scorei
- 3.77
PEG uses trailing P/E against the 3-year net income growth rate (11.30%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.94B | 2.31B | 3.03B | 3.44B | 3.94B | 4.30B | 5.00B | 5.65B |
| Gross profit | 422.22M | 513.00M | 682.26M | 779.61M | 866.92M | 981.22M | 1.01B | 1.09B |
| Selling & admin expenses | 345.88M | 459.63M | 500.20M | 525.71M | 566.12M | 607.43M | 630.25M | 682.45M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 38.27M | -319.00K | 110.76M | 190.84M | 240.23M | 314.60M | 321.83M | 337.91M |
| Pretax profit | -8.77M | -78.19M | -5.24M | 116.49M | 205.77M | 358.74M | 283.60M | 282.90M |
| Tax | -2.65M | -2.27M | 2.83M | -23.40M | 55.21M | 91.65M | 71.78M | 75.32M |
| Net profit | -6.12M | -75.92M | -8.08M | 139.90M | 150.56M | 267.09M | 211.82M | 207.59M |
| Basic EPS | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | -0.04 | -0.49 | -0.04 | 0.77 | 0.83 | 1.48 | 1.23 | 1.27 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 1.33B | 1.42B | 1.44B | 1.47B | 1.35B | 1.44B |
| Gross profit | 263.05M | 269.04M | 272.90M | 282.90M | 262.01M | 267.25M |
| Selling & admin expenses | 168.12M | 170.09M | 172.10M | 172.14M | 174.56M | 164.66M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 79.19M | 82.71M | 84.51M | 91.50M | 72.55M | 85.14M |
| Pretax profit | 63.56M | 68.86M | 68.97M | 81.52M | 61.00M | 73.99M |
| Tax | 16.81M | 18.34M | 17.15M | 23.01M | 15.66M | 20.07M |
| Net profit | 46.74M | 50.52M | 51.82M | 58.50M | 45.34M | 53.91M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.28 | 0.31 | 0.32 | 0.37 | 0.29 | 0.35 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 174.71M | 558.65M | 657.01M | 710.26M | 994.34M | 1.09B | 1.32B | 1.26B |
| Cash & ST investments | 14.54M | 67.06M | 99.27M | 119.42M | 294.19M | 343.85M | 412.57M | 232.62M |
| Inventory | 26.69M | 115.88M | 158.60M | 183.10M | 224.28M | 274.00M | 388.13M | 471.15M |
| Total assets | 583.94M | 2.59B | 2.65B | 2.79B | 3.11B | 3.22B | 3.42B | 3.46B |
| Total current liabilities | 107.32M | 330.00M | 434.02M | 459.70M | 565.35M | 618.31M | 780.15M | 829.35M |
| Short-term debt | 3.18M | 29.64M | 28.14M | 25.09M | 25.38M | 24.28M | 28.56M | 30.78M |
| Long-term debt | 501.50M | 1.28B | 1.12B | 1.06B | 1.06B | 1.06B | 1.10B | 1.15B |
| Total liabilities | 727,942,000.00 | 1,682,720,000.00 | 1,631,715,000.00 | 1,615,032,000.00 | 1,726,833,000.00 | 1,795,363,000.00 | 2,017,505,000.00 | 2,129,376,000.00 |
| Total equity | -144.00M | 906.83M | 1.02B | 1.18B | 1.39B | 1.42B | 1.40B | 1.33B |
| Retained earnings | -761.20M | -91.96M | -100.03M | 39.87M | 190.42M | 457.51M | 669.34M | 876.92M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.10B | 1.18B | 1.28B | 1.26B | 1.20B | 1.20B |
| Cash & ST investments | 171.37M | 198.82M | 309.82M | 232.62M | 177.32M | 193.77M |
| Inventory | 369.03M | 403.54M | 415.72M | 471.15M | 415.69M | 399.61M |
| Total assets | 3.31B | 3.38B | 3.48B | 3.46B | 3.38B | 3.38B |
| Total current liabilities | 713.66M | 773.62M | 823.91M | 829.35M | 729.75M | 819.48M |
| Short-term debt | 28.98M | 29.82M | 30.26M | 30.78M | 30.82M | 29.87M |
| Long-term debt | 1.10B | 1.10B | 1.16B | 1.15B | 1.15B | 1.15B |
| Total liabilities | 1,957,679,000.00 | 2,022,878,000.00 | 2,121,186,000.00 | 2,129,376,000.00 | 2,029,031,000.00 | 2,118,879,000.00 |
| Total equity | 1.35B | 1.36B | 1.36B | 1.33B | 1.35B | 1.26B |
| Retained earnings | 716.08M | 766.60M | 818.42M | 876.92M | 922.26M | 976.18M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 24.43M | 39.47M | 127.39M | 208.57M | 267.55M | 371.30M | 323.39M | 258.45M |
| Depreciation & amortization | 41.06M | 57.87M | 77.90M | 68.80M | 65.43M | 62.20M | 63.50M | 70.69M |
| Free cash flow | -1.85M | 11.18M | 100.52M | 182.94M | 232.19M | 329.43M | 287.79M | 217.14M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 118.93M | 0 | 0 | -250.26M | -252.73M | -309.95M |
| Ending cash balance | 36.39M | 67.06M | 99.27M | 119.42M | 294.19M | 343.85M | 412.57M | 232.62M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -7.21M | 90.33M | 139.44M | 35.89M | -12.11M | 183.60M |
| Depreciation & amortization | 16.37M | 16.95M | 17.05M | 20.32M | 15.66M | 18.38M |
| Free cash flow | -16.59M | 81.24M | 130.24M | 22.25M | -21.16M | 172.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -100.22M | -52.21M | -62.46M | -95.06M | -17.54M | -153.01M |
| Ending cash balance | 171.37M | 198.82M | 309.82M | 232.62M | 177.32M | 193.77M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -- | -19.91 | -0.84 | 12.77 | 11.75 | 19.03 | 14.99 | 15.20 |
| ROA %i | -10.60 | -4.78 | -0.31 | 5.14 | 5.10 | 8.44 | 6.38 | 6.04 |
| ROIC %i | -- | -0.33 | 3.14 | 8.27 | 7.79 | 11.90 | 9.54 | 9.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 4.56 | 11.54 | 14.75 |
| EBIT margin %i | 2.45 | -0.19 | 3.38 | 5.34 | 6.58 | 9.53 | 6.66 | 5.97 |
| FCF / sales %i | -- | 0.48 | 3.31 | 5.32 | 5.89 | 7.66 | 5.76 | 3.84 |
| Current ratioi | 1.63 | 1.69 | 1.51 | 1.55 | 1.76 | 1.77 | 1.70 | 1.53 |
| Quick ratioi | 1.21 | 1.19 | 0.99 | 1.00 | 1.19 | 1.17 | 1.05 | 0.85 |
| Debt / assetsi | 86.43 | 52.72 | 45.86 | 41.54 | 37.10 | 36.26 | 35.60 | 36.85 |
| LT debt / equityi | -- | 147.27 | 116.75 | 96.47 | 81.50 | 80.34 | 84.70 | 93.68 |
| Interest coveragei | -- | -0.06 | 0.95 | 2.74 | 4.82 | 8.00 | 6.78 | 6.19 |
| Revenue CAGR (3Y) %i | 25.46 | 35.17 | 54.82 | 21.03 | 19.52 | 12.36 | 13.28 | 12.72 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | 14.83 | 11.30 |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | 174.91 | 48.54 | 16.30 | -2.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 15.38 | 15.25 | 15.02 | 15.20 | 15.26 | 16.00 |
| ROA %i | 6.52 | 6.28 | 6.06 | 6.04 | 6.17 | 6.20 |
| ROIC %i | 9.66 | 9.52 | 9.40 | 9.48 | 9.48 | 9.75 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 6.54 | 6.29 | 6.06 | 5.97 | 5.91 | 5.97 |
| FCF / sales %i | 6.67 | 4.49 | 3.99 | 3.84 | 3.75 | 5.34 |
| Current ratioi | 1.54 | 1.52 | 1.56 | 1.53 | 1.64 | 1.47 |
| Quick ratioi | 0.91 | 0.88 | 0.95 | 0.85 | 0.95 | 0.91 |
| Debt / assetsi | 36.96 | 36.32 | 36.67 | 36.85 | 37.58 | 37.53 |
| LT debt / equityi | 88.39 | 88.16 | 91.70 | 93.68 | 91.73 | 98.28 |
| Interest coveragei | 6.92 | 6.64 | 6.36 | 6.19 | 6.13 | 6.27 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Single-engine
- Infusion Services is the largest reported line at 98.22% of revenue, across 2 reported segments.
- The next-largest line, Other revenue, is a distant second at 1.78% - a sharp slowdown here would have little to offset it.
Revenue breakdown most recent period
Business
Infusion Services98.22%
Other revenue1.78%
Quote time 2026-10-08 08:16:34 · For reference only, not investment advice and not tailored to your situation.